134598-03-1

Usage

Uses

Used in Organic Synthesis:
(S)-2-((2-NITROPHENOXY)METHYL)OXIRANE is used as a reagent in organic synthesis for the creation of various organic compounds. Its unique structure allows for a wide range of reactions, making it a valuable building block in the development of new molecules.
Used in Pharmaceutical Production:
In the pharmaceutical industry, (S)-2-((2-NITROPHENOXY)METHYL)OXIRANE is utilized as a key component in the production of various drugs. Its properties and reactivity contribute to the synthesis of active pharmaceutical ingredients, potentially leading to the development of novel medications.
Used in Agrochemicals:
(S)-2-((2-NITROPHENOXY)METHYL)OXIRANE is also employed in the agrochemical sector, where it serves as a reagent in the synthesis of compounds used in agriculture, such as pesticides and herbicides. Its incorporation into these products can enhance their effectiveness and selectivity.
Used in Polymer Synthesis:
This chemical compound is used as a building block in the synthesis of polymers, which are large molecules composed of repeating structural units. Its unique structure allows for the creation of polymers with specific properties, making it a valuable asset in the development of new materials.
Used in Medicinal Chemistry:
(S)-2-((2-NITROPHENOXY)METHYL)OXIRANE has been studied for its potential biological and pharmacological properties, showing promise for use in medicinal chemistry. Its unique structure and reactivity make it a candidate for the development of new drugs and therapeutic agents.

Upstream product

• 115314-14-2 (2s)-(+)-glycidyl 3-nitrobenzenesulfonate 
• 88-75-5 2-hydroxynitrobenzene 
• 21407-49-8 2-nitrophenyl glycidyl ether 

Downstream Products

• 57682-11-8 N-acetyl-2-(2,3-epoxypropoxy)aniline 

Relevant academic research and scientific papers

Chiral nanoporous metal-metallosalen frameworks for hydrolytic kinetic resolution of epoxides

Chiral nanoporous metal-organic frameworks are constructed by using dicarboxyl-functionalized chiral Ni(salen) and Co(salen) ligands. The Co(salen)-based framework is shown to be an efficient and recyclable heterogeneous catalyst for hydrolytic kinetic resolution (HKR) of racemic epoxides with up to 99.5% ee. The MOF structure brings Co(salen) units into a highly dense arrangement and close proximity that enhances bimetallic cooperative interactions, leading to improved catalytic activity and enantioselectivity in HKR compared with its homogeneous analogues, especially at low catalyst/substrate ratios.

Bacillus alcalophilus MTCC10234 catalyzed enantioselective kinetic resolution of aryl glycidyl ethers

The phenyl glycidyl ether derivatives have been kinetically resolved with the growing cells of Bacillus alcalophilus MTCC10234 yielding (S)-epoxides with up to >99% ee and (R)-diols with up to 89% ee. The enantiomeric ratio (E) of up to 67 has been obtained for biohydrolysis process. The effect of different substituents of phenyl glycidyl ether on the biocatalytic efficiency of B. alcalophilus MTCC10234 showed preference for methyl- and chloro-substituted aryl glycidyl ether derivatives whereas nitro-derivatives were transformed at a slower rate. 2,6-Dimethylphenyl glycidyl ether which contains a bulky aryl group having methyl group on both the ortho positions was resolved with an E=39.

Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists

Enantiomeric propanolamines have been identified as a new class of NR2B-selective NMDA receptor antagonists. The most effective agents are biaryl structures, synthesized in six steps with overall yields ranging from 11-64%. The compounds are potent and selective inhibitors of NR2B-containing recombinant NMDA receptors with IC50 values between 30-100 nM. Potency is strongly controlled by substitution on both rings and the centrally located amine nitrogen. SAR analysis suggests that well-balanced polarity and chain-length factors provide the greatest inhibitory potency. Structural comparisons based on 3D shape analysis and electrostatic complementarity support this conclusion. The antagonists are neuroprotective in both in vitro and in vivo models of ischemic cell death. In addition, some compounds exhibit anticonvulsant properties. Unlike earlier generation NMDA receptor antagonists and some NR2B-selective antagonists, the present series of propanolamines does not cause increased locomotion in rodents. Thus, the NR2B-selective antagonists exhibit a range of therapeutically interesting properties.